Shanghai S.E.
03:30:00 06/06/2024 am IST
5-day change
1st Jan Change
20.36
CNY
-4.23%
-13.36%
-22.79%
Nanjing Well Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2019
August 19, 2019 at 10:17 pm IST
Nanjing Well Pharmaceutical Co., Ltd. announced earnings results for the half year ended June 30, 2019. For the half year, the company announced sales was CNY 0 compared to CNY 407.453 million a year ago. Sales was CNY 437.784 million compared to CNY 0 a year ago. Sales was CNY 437.784 million compared to CNY 407.453 million a year ago. Operating income was CNY 90.551 million compared to CNY 71.849 million a year ago. Net income was CNY 76.504 million compared to CNY 61.153 million a year ago. Basic earnings per share from continuing operations was CNY 0.84 compared to CNY 0.87 a year ago.
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
25/04
CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
30/23/30
CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
28/23/28
CI
Nanjing Well Pharmaceutical Group Co.,Ltd. completed the acquisition of13% stake in Nanjing Xingwei Biotechnology Co., Ltd. from Wu Renrong, Gao Zhengsong, Chen Xinguo, Tang Qunsong, Shen Jiusi, Wu Rongwen, Hong Shilin, Zou Jianguo, Wang Fuqiu and Zhou Chong.
17/23/17
CI
Nanjing Well Pharmaceutical Group Co.,Ltd. signed an agreement to acquire 13% stake in Nanjing Xingwei Biotechnology Co., Ltd. from Wu Renrong, Gao Zhengsong, Chen Xinguo, Tang Qunsong, Shen Jiusi, Wu Rongwen, Hong Shilin, Zou Jianguo, Wang Fuqiu and Zhou Chong for CNY0.
17/23/17
CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
24/23/24
CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
24/23/24
CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
27/22/27
CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
22/22/22
CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
26/22/26
CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
18/22/18
CI
Certain A Shares of Nanjing Well Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 30-JAN-2022.
30/22/30
CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
28/21/28
CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
29/21/29
CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
26/21/26
CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020
12/21/12
CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020
23/20/23
CI
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020
19/20/19
CI
Nanjing Well Pharmaceutical Group Co.,Ltd.(XSSC:603351) dropped from S&P Global BMI Index
22/20/22
CI
Nanjing Well Pharmaceutical Co., Ltd. Announces Cash Dividend for the Year 2019, Payable on May 27, 2020
20/20/20
CI
Nanjing Well Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2020
28/20/28
CI
Nanjing Market Supervision and Administration Bureau has Changed its Name to Nanjing Well Pharmaceutical Co.,Ltd
23/20/23
CI
Nanjing Well Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2019
20/20/20
CI
Certain A Shares of Nanjing Well Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 30-JAN-2020.
30/20/30
CI
Nanjing Well Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2019
28/19/28
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Nanjing Well Pharmaceutical Group Co Ltd, formerly Nanjing Well Pharmaceutical Co Ltd, is a China-based company principally involved in the research and development, manufacturing and sales of pharmaceutical auxiliary materials and synthetic lubricating base oil products. Its main products include pharmaceutical auxiliary materials, synthetic lubricating base oil and pesticide additives. The Company distributes its products primarily in domestic market.
More about the company
1st Jan change
Capi.
-22.79% 40Cr +10.76% 23TCr +20.05% 9.93TCr +18.45% 6.13TCr +3.93% 5.82TCr +19.82% 5.04TCr +19.06% 3.48TCr +25.99% 2.63TCr -18.46% 1.96TCr +8.29% 1.92TCr
Other Oil & Gas Refining and Marketing
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
NANJING WELL PHARMACEUTICAL GROUP CO.,LTD. 
